Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha.

The CC chemokine macrophage inflammatory protein 1alpha (MIP1alpha) is a key regulator of the proliferation and differentiation of hematopoietic progenitor cells. The activity of MIP1alpha appears to be modulated by its binding to heparan sulfate (HS) proteoglycans, ubiquitous components of the mammalian cell surface and extracellular matrix. In this study we show that HS has highest affinity for the dimeric form of MIP1alpha. The predominantly dimeric BB10010 MIP1alpha interacts with an 8.3-kDa sequence in the HS polysaccharide chain, which it protects from degradation by heparinase enzymes. The major structural motif of this HS fragment appears to consist of 2 sulfate-rich S-domains separated by a short central N-acetylated region. The optimum lengths of these S-domains seem to be 12 to 14 saccharides. We propose that this binding fragment may wrap around the MIP1alpha dimer in a horseshoe shape, facilitating the interaction of the S-domains with the heparin-binding domains on each monomer. Molecular modeling suggests that these S-domains are likely to interact with basic residues Arg 17, Arg 45, and Arg 47 and possibly with Lys 44 on MIP1alpha and that the interconnecting N-acetylated region is of sufficient length to allow the 2 S-domains to bind to these sites on opposite faces of the dimer. Elucidation of the structure of the HS-binding site for MIP1alpha may enable us to devise ways of enhancing its myeloprotective or peripheral blood stem cell mobilization properties, which can be used to improve cancer chemotherapy treatments.

[1]  K. Ottersbach,et al.  Aggregation-independent modulation of proteoglycan binding by neutralization of C-terminal acidic residues in the chemokine macrophage inflammatory protein 1α , 2001 .

[2]  K. Ottersbach,et al.  Aggregation-independent modulation of proteoglycan binding by neutralization of C-terminal acidic residues in the chemokine macrophage inflammatory protein 1alpha. , 2001, The Biochemical journal.

[3]  M. Forster,et al.  Conformation and dynamics of heparin and heparan sulfate. , 2000, Glycobiology.

[4]  J. Arnold,et al.  For the record: Chemical modification of a variant of human MIP‐1α; implications for dimer structure , 2000 .

[5]  J. Arnold,et al.  Chemical modification of a variant of human MIP-1alpha; implications for dimer structure. , 2000, Protein science : a publication of the Protein Society.

[6]  T. Oegema,et al.  Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins. , 2000, Blood.

[7]  M. Krangel,et al.  Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta. , 1999, Journal of immunology.

[8]  M. Lyon,et al.  Highly Sensitive Sequencing of the Sulfated Domains of Heparan Sulfate* , 1999, The Journal of Biological Chemistry.

[9]  V. Appay,et al.  Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. , 1999, The Journal of biological chemistry.

[10]  T. Oegema,et al.  Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. , 1998, Blood.

[11]  B. Lord,et al.  CD34+AC133+ Cells Isolated from Cord Blood are Highly Enriched in Long‐Term Culture‐Initiating Cells, NOD/SCID‐Repopulating Cells and Dendritic Cell Progenitors , 1998, Stem cells.

[12]  J. Turnbull,et al.  Heparan Sulfate Oligosaccharides Require 6-O-Sulfation for Promotion of Basic Fibroblast Growth Factor Mitogenic Activity* , 1998, The Journal of Biological Chemistry.

[13]  A. Howell,et al.  A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy , 1998 .

[14]  S. Kumar,et al.  Endothelial and fibroblast cell-derived heparan sulphate bind with differing affinity to basic fibroblast growth factor. , 1998, Biochemical and biophysical research communications.

[15]  D. Spillmann,et al.  Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.

[16]  F. Melo,et al.  Assessing protein structures with a non-local atomic interaction energy. , 1998, Journal of molecular biology.

[17]  A. Howell,et al.  A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. , 1998, Blood.

[18]  C. Power,et al.  Glycosaminoglycans mediate cell surface oligomerization of chemokines. , 1997, Biochemistry.

[19]  S. Stringer,et al.  Specific Binding of the Chemokine Platelet Factor 4 to Heparan Sulfate* , 1997, The Journal of Biological Chemistry.

[20]  B. Lord,et al.  Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide. , 1997, British Journal of Cancer.

[21]  M. Krangel,et al.  Identification of a Glycosaminoglycan-binding Site in Chemokine Macrophage Inflammatory Protein-1α* , 1997, The Journal of Biological Chemistry.

[22]  I. Lemischka Microenvironmental regulation of hematopoietic stem cells , 1997, Stem cells.

[23]  F. Ruscetti,et al.  Raf‐1 Protein is Required for Growth Factor‐Induced Proliferation of Primitive Hematopoietic Progenitors Stimulated with Synergistic Combinations of Cytokines , 1997, Stem cells.

[24]  J. Gallagher,et al.  Molecules in focus: heparan sulphate , 1997 .

[25]  S. Stringer,et al.  Heparan sulphate. , 1997, The international journal of biochemistry & cell biology.

[26]  R. Nibbs,et al.  Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP‐1alpha by mutagenesis of the proteoglycan binding site. , 1996, The EMBO journal.

[27]  David S. Goodsell,et al.  Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 , 1996, J. Comput. Aided Mol. Des..

[28]  A. H. Drummond,et al.  BB-10010: an active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties. , 1995, Blood.

[29]  V. Roongta,et al.  Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding. , 1995, The Biochemical journal.

[30]  J. Turnbull,et al.  Molecular organization of the interferon gamma-binding domain in heparan sulphate. , 1995, The Biochemical journal.

[31]  A. Lander,et al.  Differential binding of chemokines to glycosaminoglycan subpopulations , 1994, Current Biology.

[32]  M. Lyon,et al.  Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. , 1994, The Journal of biological chemistry.

[33]  A. Drake,et al.  The effect of variation of substitution on the solution conformation of heparin: a spectroscopic and molecular modelling study. , 1994, Carbohydrate research.

[34]  M. Tsang,et al.  Aggregation of the chemokine MIP-1 alpha is a dynamic and reversible phenomenon. Biochemical and biological analyses. , 1994, The Journal of biological chemistry.

[35]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[36]  M. Forster,et al.  N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.

[37]  N. Testa,et al.  Haemopoiesis : a practical approach , 1993 .

[38]  A. French,et al.  Conformational analysis of the anomeric forms of sophorose, laminarabiose, and cellobiose using MM3. , 1992, Carbohydrate research.

[39]  A. French,et al.  Conformational analysis of the anomeric forms of kojibiose, nigerose, and maltose using MM3. , 1992, Carbohydrate research.

[40]  T. Dexter,et al.  Macrophage-inflammatory protein protects multipotent hematopoietic cells from the cytotoxic effects of hydroxyurea in vivo. , 1992, Blood.

[41]  P. Quesenberry,et al.  Stem cell factor induction of in vitro murine hematopoietic colony formation by "subliminal" cytokine combinations: the role of "anchor factors". , 1992, Blood.

[42]  E. Wright,et al.  Identification and characterization of an inhibitor of haemopoietic stem cell proliferation , 1990, Nature.

[43]  R. Linhardt,et al.  Examination of the substrate specificity of heparin and heparan sulfate lyases. , 1990, Biochemistry.

[44]  J. Turnbull,et al.  Molecular organization of heparan sulphate from human skin fibroblasts. , 1990, The Biochemical journal.

[45]  J. Loscalzo,et al.  The interaction of platelet factor four and glycosaminoglycans. , 1985, Archives of biochemistry and biophysics.

[46]  J. Shively,et al.  Formation of anhydrosugars in the chemical depolymerization of heparin. , 1976, Biochemistry.

[47]  H. Cohen,et al.  Purification and binding properties of human platelet factor four. , 1976, The Journal of biological chemistry.

[48]  Å. Wasteson A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate. , 1971, Journal of chromatography.